Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease

Paolo G. Gobbi, Carla Pieresca, Maria L. Ghirardelli, Nicola Di Renzo, Massimo Federico, Francesco Merli, Emilio Iannitto, Vincenzo Pitini, Giovanni Grignani, Amedea Donelli, Mario Carotenuto, Vittorio Silingardi, Edoardo Ascari

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The purpose was to verify the 5-year results of the MOPPEBVCAD chemotherapy regimen with limited radiotherapy in relation to the promising preliminary data. Mechlorethamine, vincristine, procarbazine, prednisone, epidoxorubicin, bleomycin, vinblastine, lomustine, melphalan, and vindesine were delivered according to a schedule derived through hybridization, intensification, and shortening of the corresponding alternating CAD/MOPP/ABV regimen. Radiotherapy was restricted to sites of bulky involvement or to areas that responded incompletely to chemotherapy. This multicenter, controlled, nonradomized trial involved 145 eligible patients. Radiotherapy was administered to 47 patients, 46 of whom were in complete remission after chemotherapy. Remissions were complete in 137 patients (94%), partial in 4 (3%), and null in the remaining 4. Tumor-specific, overall, relapse-free, and failure-free survival at 5 years were 0.89, 0.86, 0.82, and 0.78, respectively. Hematologic toxicity was considerable, whereas nonhematologic side effects were fully acceptable. Most of the unfavorable prognostic factors lost their clinical weight. Only age and lymphocyte depletion histologic type were statistically correlated with major follow-up endpoints; performance status and bone marrow involvement were subordinate to age. Seven patients developed a second cancer (including 3 myelodysplasias). MOPPEBVCAD with selected radiotherapy is a highly effective regimen in advanced Hodgkin's disease. Early and late toxicity are no more severe than what would be expected with other alternating or hybrid regimens. A comparison with ABVD, which is currently considered the standard regimen for advanced Hodgkin's disease, is needed.

Original languageEnglish
Pages (from-to)2704-2712
Number of pages9
JournalBlood
Volume91
Issue number8
Publication statusPublished - Apr 15 1998

Fingerprint

Chemotherapy
Radiotherapy
Hodgkin Disease
Drug Therapy
Toxicity
Vindesine
Lomustine
Lymphocyte Depletion
Procarbazine
Mechlorethamine
Melphalan
Second Primary Neoplasms
Lymphocytes
Vinblastine
Bleomycin
Vincristine
Prednisone
Tumors
Computer aided design
Appointments and Schedules

ASJC Scopus subject areas

  • Hematology

Cite this

Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease. / Gobbi, Paolo G.; Pieresca, Carla; Ghirardelli, Maria L.; Di Renzo, Nicola; Federico, Massimo; Merli, Francesco; Iannitto, Emilio; Pitini, Vincenzo; Grignani, Giovanni; Donelli, Amedea; Carotenuto, Mario; Silingardi, Vittorio; Ascari, Edoardo.

In: Blood, Vol. 91, No. 8, 15.04.1998, p. 2704-2712.

Research output: Contribution to journalArticle

Gobbi, PG, Pieresca, C, Ghirardelli, ML, Di Renzo, N, Federico, M, Merli, F, Iannitto, E, Pitini, V, Grignani, G, Donelli, A, Carotenuto, M, Silingardi, V & Ascari, E 1998, 'Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease', Blood, vol. 91, no. 8, pp. 2704-2712.
Gobbi, Paolo G. ; Pieresca, Carla ; Ghirardelli, Maria L. ; Di Renzo, Nicola ; Federico, Massimo ; Merli, Francesco ; Iannitto, Emilio ; Pitini, Vincenzo ; Grignani, Giovanni ; Donelli, Amedea ; Carotenuto, Mario ; Silingardi, Vittorio ; Ascari, Edoardo. / Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease. In: Blood. 1998 ; Vol. 91, No. 8. pp. 2704-2712.
@article{8d680b4a939549a7a1ee1bedc44a27df,
title = "Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease",
abstract = "The purpose was to verify the 5-year results of the MOPPEBVCAD chemotherapy regimen with limited radiotherapy in relation to the promising preliminary data. Mechlorethamine, vincristine, procarbazine, prednisone, epidoxorubicin, bleomycin, vinblastine, lomustine, melphalan, and vindesine were delivered according to a schedule derived through hybridization, intensification, and shortening of the corresponding alternating CAD/MOPP/ABV regimen. Radiotherapy was restricted to sites of bulky involvement or to areas that responded incompletely to chemotherapy. This multicenter, controlled, nonradomized trial involved 145 eligible patients. Radiotherapy was administered to 47 patients, 46 of whom were in complete remission after chemotherapy. Remissions were complete in 137 patients (94{\%}), partial in 4 (3{\%}), and null in the remaining 4. Tumor-specific, overall, relapse-free, and failure-free survival at 5 years were 0.89, 0.86, 0.82, and 0.78, respectively. Hematologic toxicity was considerable, whereas nonhematologic side effects were fully acceptable. Most of the unfavorable prognostic factors lost their clinical weight. Only age and lymphocyte depletion histologic type were statistically correlated with major follow-up endpoints; performance status and bone marrow involvement were subordinate to age. Seven patients developed a second cancer (including 3 myelodysplasias). MOPPEBVCAD with selected radiotherapy is a highly effective regimen in advanced Hodgkin's disease. Early and late toxicity are no more severe than what would be expected with other alternating or hybrid regimens. A comparison with ABVD, which is currently considered the standard regimen for advanced Hodgkin's disease, is needed.",
author = "Gobbi, {Paolo G.} and Carla Pieresca and Ghirardelli, {Maria L.} and {Di Renzo}, Nicola and Massimo Federico and Francesco Merli and Emilio Iannitto and Vincenzo Pitini and Giovanni Grignani and Amedea Donelli and Mario Carotenuto and Vittorio Silingardi and Edoardo Ascari",
year = "1998",
month = "4",
day = "15",
language = "English",
volume = "91",
pages = "2704--2712",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease

AU - Gobbi, Paolo G.

AU - Pieresca, Carla

AU - Ghirardelli, Maria L.

AU - Di Renzo, Nicola

AU - Federico, Massimo

AU - Merli, Francesco

AU - Iannitto, Emilio

AU - Pitini, Vincenzo

AU - Grignani, Giovanni

AU - Donelli, Amedea

AU - Carotenuto, Mario

AU - Silingardi, Vittorio

AU - Ascari, Edoardo

PY - 1998/4/15

Y1 - 1998/4/15

N2 - The purpose was to verify the 5-year results of the MOPPEBVCAD chemotherapy regimen with limited radiotherapy in relation to the promising preliminary data. Mechlorethamine, vincristine, procarbazine, prednisone, epidoxorubicin, bleomycin, vinblastine, lomustine, melphalan, and vindesine were delivered according to a schedule derived through hybridization, intensification, and shortening of the corresponding alternating CAD/MOPP/ABV regimen. Radiotherapy was restricted to sites of bulky involvement or to areas that responded incompletely to chemotherapy. This multicenter, controlled, nonradomized trial involved 145 eligible patients. Radiotherapy was administered to 47 patients, 46 of whom were in complete remission after chemotherapy. Remissions were complete in 137 patients (94%), partial in 4 (3%), and null in the remaining 4. Tumor-specific, overall, relapse-free, and failure-free survival at 5 years were 0.89, 0.86, 0.82, and 0.78, respectively. Hematologic toxicity was considerable, whereas nonhematologic side effects were fully acceptable. Most of the unfavorable prognostic factors lost their clinical weight. Only age and lymphocyte depletion histologic type were statistically correlated with major follow-up endpoints; performance status and bone marrow involvement were subordinate to age. Seven patients developed a second cancer (including 3 myelodysplasias). MOPPEBVCAD with selected radiotherapy is a highly effective regimen in advanced Hodgkin's disease. Early and late toxicity are no more severe than what would be expected with other alternating or hybrid regimens. A comparison with ABVD, which is currently considered the standard regimen for advanced Hodgkin's disease, is needed.

AB - The purpose was to verify the 5-year results of the MOPPEBVCAD chemotherapy regimen with limited radiotherapy in relation to the promising preliminary data. Mechlorethamine, vincristine, procarbazine, prednisone, epidoxorubicin, bleomycin, vinblastine, lomustine, melphalan, and vindesine were delivered according to a schedule derived through hybridization, intensification, and shortening of the corresponding alternating CAD/MOPP/ABV regimen. Radiotherapy was restricted to sites of bulky involvement or to areas that responded incompletely to chemotherapy. This multicenter, controlled, nonradomized trial involved 145 eligible patients. Radiotherapy was administered to 47 patients, 46 of whom were in complete remission after chemotherapy. Remissions were complete in 137 patients (94%), partial in 4 (3%), and null in the remaining 4. Tumor-specific, overall, relapse-free, and failure-free survival at 5 years were 0.89, 0.86, 0.82, and 0.78, respectively. Hematologic toxicity was considerable, whereas nonhematologic side effects were fully acceptable. Most of the unfavorable prognostic factors lost their clinical weight. Only age and lymphocyte depletion histologic type were statistically correlated with major follow-up endpoints; performance status and bone marrow involvement were subordinate to age. Seven patients developed a second cancer (including 3 myelodysplasias). MOPPEBVCAD with selected radiotherapy is a highly effective regimen in advanced Hodgkin's disease. Early and late toxicity are no more severe than what would be expected with other alternating or hybrid regimens. A comparison with ABVD, which is currently considered the standard regimen for advanced Hodgkin's disease, is needed.

UR - http://www.scopus.com/inward/record.url?scp=0032523092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032523092&partnerID=8YFLogxK

M3 - Article

VL - 91

SP - 2704

EP - 2712

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -